Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alpha-Tochopherol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.89 |
| ▸ | TTPA | P49638 | 3/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.89 |
| ▸ | USP2 | O75604 | 1/20 | 0.89 |
| ▸ | THRB | P10828 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.81 |
| ▸ | PDE4A | P27815 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.70 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.67 |
| ▸ | AKT1 | P31749 | 2/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Tocopherol SCHEMBL28174566 | 1.00 | LMNA (0.89) | LMNATTPAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL28174565 | 1.00 | LMNA (0.89) | LMNATTPAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL27538180 | 1.00 | LMNA (0.89) | LMNATTPAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL27177 | 1.00 | LMNA (0.89) | LMNATTPAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL4083978 | 1.00 | LMNA (0.89) | LMNATTPAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL5868266 | 0.99 | LMNA (0.88) | LMNATTPAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL28110607 | 0.96 | LMNA (0.82) | LMNATTPAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL4556023 | 0.96 | LMNA (0.82) | LMNATTPAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL27696980 | 0.96 | LMNA (0.89) | LMNATTPAMAPTMEN1KMT2A | |
| Alpha-Tocopherol SCHEMBL359184 | 0.95 | LMNA (0.84) | LMNATTPAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245600-A1 | ORRIS ROOT EXTRACTS, COMPOSITIONS, AND METHODS FOR SKIN APPLICATIONS | ACCESS BUSINESS GROUP INT LLC (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240123010-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | AVENIR WELLNESS SOLUTIONS INC (US) | 2024-04-18 | — | — | US | disclosed |
| CN-117794504-A | Iris root extract, compositions and methods for dermatological use | 捷通国际有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11938160-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2024-03-26 | — | — | US | disclosed |
| US-11890310-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2024-02-06 | — | — | US | disclosed |
| US-11844763-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2023-12-19 | — | — | US | disclosed |
| US-20230085079-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2023-03-16 | — | — | US | disclosed |
| WO-2022256476-A1 | ORRIS ROOT EXTRACTS, COMPOSITIONS, AND METHODS FOR SKIN APPLICATIONS | ACCESS BUSINESS GROUP INTERNATIONAL LLC (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220370529-A1 | CANNABIS COMPOSITIONS AND RELATED METHODS | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2022-11-24 | — | — | US | disclosed |
| US-11478520-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-10-25 | — | — | US | disclosed |
| WO-2006060475-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| US-6830758-B2 | Patch containing drug; flexible backing; pressure sensitive adhesive | LECTEC CORPORATION | 2004-12-14 | — | — | US | disclosed |
| US-20040071757-A1 | Inhalation antiviral patch | LECTEC CORPORATION | 2004-04-15 | — | — | US | disclosed |
| US-20030152610-A1 | Adhesive with flexible backing; exfoliate, hydrate skin | LECTEC CORPORATION | 2003-08-14 | — | — | US | disclosed |
| WO-2003063817-A1 | COSMETIC PATCH | LECTEC CORPORATION (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030077316-A1 | Psoriasis patch | AXOGEN CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20020192273-A1 | Therapeutic patch useful for the treatment of hemorrhoids | LEC TEC CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6495158-B1 | MIXTURE OF SOLVENTS, TOPICAL DRUGS AND PRESSURE SENSITIVE OR HOT MELT ADHESIVES HAVING FLEXIBLE BACKINGS COMPRISING NONWOVEN FABRIC TREATED WITH SILICONE SIZING AGENTS TO CONTROL PERMEABILITY | LEC TEC CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6469227-B1 | Antipruritic patch | LECTEC CORPORATION | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844763-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | LMNA 4008/4885TTPA 2149/4885MAPT 94/4885 |
| US-20230085079-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | LMNA 4008/4885TTPA 2149/4885MAPT 94/4885 |
| US-11890310-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | LMNA 4008/4885TTPA 2149/4885MAPT 94/4885 |
| US-20020192273-A1 | Therapeutic patch useful for the treatment of hemorrhoids | PTGIR, PLOD3, PTGIS | LMNA 1538/4885TTPA 709/4885MAPT 3260/4885 |
| US-20220370529-A1 | CANNABIS COMPOSITIONS AND RELATED METHODS | CNR2, CNR1, S100P | LMNA 4586/4885TTPA 1666/4885MAPT 1434/4885 |
| US-11478520-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | LMNA 4008/4885TTPA 2149/4885MAPT 94/4885 |
| US-20240123010-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | LMNA 4008/4885TTPA 2149/4885MAPT 94/4885 |
| US-11938160-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | LMNA 4008/4885TTPA 2149/4885MAPT 94/4885 |
| US-20040071757-A1 | Inhalation antiviral patch | ICAM1, EPCAM, GJA1 | LMNA 1491/4885TTPA 586/4885MAPT 4189/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | LMNA 9/4885TTPA 876/4885MAPT 1161/4885 |
| US-20030152610-A1 | Adhesive with flexible backing; exfoliate, hydrate skin | EPCAM, DSG1, CDH1 | LMNA 605/4885TTPA 318/4885MAPT 928/4885 |
| US-20030077316-A1 | Psoriasis patch | PEF1, ITCH, DSG1 | LMNA 1479/4885TTPA 2361/4885MAPT 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.